Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.
GSK (NYSE:GSK) today announced that China’s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype.
IDEAYA Biosciences (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the first-patient-in (FPI) for its Phase 1 clinical trial evaluating the combination of IDE849 and IDE161.
enVVeno Medical (NASDAQ:NVNO), a clinical-stage medical device company developing innovative solutions for the treatment of chronic venous insufficiency (CVI), today reported its financial results for the full year ended December 31, 2025.
Humacyte (NASDAQ:HUMA), a pioneer in universally implantable, bioengineered human tissues, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
SBC Medical Group Holdings (NASDAQ:SBC), a leading Management Services Organization (MSO) for a diverse range of medical franchises, today announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
Kiora Pharmaceuticals (NASDAQ:KPRX) released its fourth-quarter and full-year 2025 financial results on Wednesday, detailing a streamlined balance sheet and steady clinical momentum for its pipeline of retinal disease treatments.
Sanara MedTech (NASDAQ:SMTI) today announced its financial results for the fourth quarter and full year ended December 31, 2025, marking the first time the company has surpassed the $100 million annual revenue threshold.
Neurogene (NASDAQ:NGNE) today reported financial results for the fourth quarter and full year ended December 31, 2025, delivering a "beat" against Wall Street’s bottom-line expectations.
LENZ Therapeutics (NASDAQ:LENZ) today reported its financial results for the fourth quarter and full year ended December 31, 2025, providing the first comprehensive look at the commercial performance of VIZZ® (aceclidine 1.44%).
Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).
